Glioblastoma (GBM) clinical trials
Showing 101–150 of 196 active trials. Describe your situation to see which ones you may be eligible for.
- Study of Pembrolizumab and M032 (NSC 733972)
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
- Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
- DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- A Study of 177Lu-PSMA-617 in People With Gliomas
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
- A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
- Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
- Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
- Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
- Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
- WBSI Guided Personalized Delivery of TTFields
- Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- Evaluation of the CONVIVO System
- Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
- Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC
- Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
- Loupe-Based Intraoperative Fluorescence Imaging
- The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
- BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
- Impact of ICCAN on Cancer Treatment Completion and Quality of Life
- Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
- The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
- Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Targeted Pediatric High-Grade Glioma Therapy
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.